Brookdale Senior Living Inc.

DB:B7S Stock Report

Market Cap: €1.1b

Brookdale Senior Living Valuation

Is B7S undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of B7S when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: B7S (€5.25) is trading above our estimate of fair value (€4.2)

Significantly Below Fair Value: B7S is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for B7S?

Key metric: As B7S is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for B7S. This is calculated by dividing B7S's market cap by their current revenue.
What is B7S's PS Ratio?
PS Ratio0.4x
SalesUS$2.95b
Market CapUS$1.13b

Price to Sales Ratio vs Peers

How does B7S's PS Ratio compare to its peers?

The above table shows the PS ratio for B7S vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1x
RHK RHÖN-KLINIKUM
0.5x2.1%€856.8m
M12 M1 Kliniken
0.9x8.2%€294.1m
MED MEDICLIN
0.2x0.7%€117.8m
LIK LIMES Schlosskliniken
2.3x17.7%€97.9m
B7S Brookdale Senior Living
0.4x5.6%€1.1b

Price-To-Sales vs Peers: B7S is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does B7S's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
TLIK Arzneiwerk VIDA
0.08xn/aUS$4.95m
EIF MedNation
0.1xn/aUS$4.85m
No more companies available in this PS range
B7S 0.4xIndustry Avg. 0.6xNo. of Companies3PS00.40.81.21.62+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: B7S is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is B7S's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

B7S PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: B7S is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst B7S forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.25
€7.03
+33.8%
14.7%€7.62€5.24n/a4
Nov ’25€5.75
€7.14
+24.1%
14.1%€8.29€5.53n/a4
Oct ’25€6.05
€7.41
+22.5%
6.5%€8.08€6.96n/a3
Sep ’25€6.35
€7.56
+19.0%
6.5%€8.24€7.10n/a3
Aug ’25€7.20
€7.47
+3.7%
8.1%€8.32€6.93n/a3
Jul ’25€6.30
€7.55
+19.8%
8.1%€8.40€7.00n/a3
Jun ’25€6.10
€7.79
+27.8%
7.5%€8.38€7.21n/a2
May ’25€6.40
€7.46
+16.5%
12.5%€8.39€6.53n/a2
Apr ’25€6.05
€7.16
+18.4%
16.1%€8.32€6.01n/a2
Mar ’25€5.25
€7.16
+36.4%
16.1%€8.32€6.01n/a2
Feb ’25€5.05
€6.88
+36.2%
20.0%€8.26€5.50n/a2
Jan ’25€5.40
€6.88
+27.4%
20.0%€8.26€5.50n/a2
Dec ’24€4.84
€5.94
+22.7%
39.0%€8.25€3.62€5.252
Nov ’24€3.68
€5.17
+40.5%
27.9%€6.61€3.73€5.752
Oct ’24€3.76
€5.55
+47.6%
24.0%€6.49€3.66€6.053
Sep ’24€3.90
€5.55
+42.3%
24.0%€6.49€3.66€6.353
Aug ’24€3.18
€5.55
+74.6%
24.0%€6.49€3.66€7.203
Jul ’24€3.84
€5.55
+44.6%
24.0%€6.49€3.66€6.303
Jun ’24€3.20
€5.15
+61.0%
22.5%€6.38€3.60€6.103
May ’24€3.82
€5.06
+32.5%
24.3%€6.34€3.40€6.403
Apr ’24€2.74
€4.76
+73.8%
29.7%€6.58€3.06€6.054
Mar ’24€3.04
€4.76
+56.7%
26.6%€6.60€3.07€5.255
Feb ’24€2.62
€4.45
+69.8%
27.6%€6.49€2.78€5.055
Jan ’24€2.56
€4.91
+91.6%
25.5%€6.60€2.83€5.405
Dec ’23€3.00
€5.29
+76.4%
18.3%€6.83€4.00€4.845

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

LNA Santé

€241.3m

Engages in the management and operation of health establishments.

2N3

€22.65

7D

-2.6%

1Y

18.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%

OrbusNeich Medical Group Holdings

HK$3.1b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

Q8T

HK$0.39

7D

-23.6%

1Y

-42.8%